摘要 Objective: Serum prostate specific antigen (PSA) is commonly used to evaluate treatment response after definitive radiation therapy (RT). However, PSA levels can temporarily rise without a clear reason, termed "PSA bounce", and often engender great anxiety for both patients and physicians. The present study aimed to determine the prevalence and factors that predict "PSA bounce" after intensity-modulated radiation therapy (IMRT), and the relevance to biochemical failure and cancer recurrence in an Asian population. Methods: We retrospectively reviewed 206 patients who received IMRT for prostate cancer from 2004 to 2012 in the National Cancer Centre Singapore. These patients were followed up with regular PSA monitoring. We defined "PSA bounce" as a rise of 0.1 ng/mL, followed by two consecutive falls. Patients with biochemical failure (PSA nadir + 2 ng/mL) were further evaluated for cancer recurrence. Results: Sixty-one patients (29.6%) experienced "PSA bounce", at a median time of 16 months and lasted for 12 months. Age remained the most consistent predictor of the incidence, duration and extent of "PSA bounce". Other contributory factors included baseline PSA, Gleason score and PSA nadir. Hormonal therapy and prostate volume did not affect this phenomenon. Sixteen patients (7.8%) developed biochemical recurrence, at median time of 32 months, of which 11 were confirmed to have metastatic disease. The median follow-up time was 71 months. Conclusion: A younger age predicts PSA bounce incidence, duration and magnitude. The extent of bounce appears to be lower in Asian population. The interval to occurrence and extent of PSA elevation separates PSA bounce from disease recurrence.
Abstract: Objective: Serum prostate specific antigen (PSA) is commonly used to evaluate treatment response after definitive radiation therapy (RT). However, PSA levels can temporarily rise without a clear reason, termed "PSA bounce", and often engender great anxiety for both patients and physicians. The present study aimed to determine the prevalence and factors that predict "PSA bounce" after intensity-modulated radiation therapy (IMRT), and the relevance to biochemical failure and cancer recurrence in an Asian population. Methods: We retrospectively reviewed 206 patients who received IMRT for prostate cancer from 2004 to 2012 in the National Cancer Centre Singapore. These patients were followed up with regular PSA monitoring. We defined "PSA bounce" as a rise of 0.1 ng/mL, followed by two consecutive falls. Patients with biochemical failure (PSA nadir + 2 ng/mL) were further evaluated for cancer recurrence. Results: Sixty-one patients (29.6%) experienced "PSA bounce", at a median time of 16 months and lasted for 12 months. Age remained the most consistent predictor of the incidence, duration and extent of "PSA bounce". Other contributory factors included baseline PSA, Gleason score and PSA nadir. Hormonal therapy and prostate volume did not affect this phenomenon. Sixteen patients (7.8%) developed biochemical recurrence, at median time of 32 months, of which 11 were confirmed to have metastatic disease. The median follow-up time was 71 months. Conclusion: A younger age predicts PSA bounce incidence, duration and magnitude. The extent of bounce appears to be lower in Asian population. The interval to occurrence and extent of PSA elevation separates PSA bounce from disease recurrence.
Yu Guang Tan, Weber Lau Kam On, Hong Hong Huang, Terence Tan Wee Kiat. Prostate specific antigen bounce after intensity-modulated radiation therapy in an Asian population[J]. Asian Journal of Urology, 2016, 3(2): 59-63.
Yu Guang Tan, Weber Lau Kam On, Hong Hong Huang, Terence Tan Wee Kiat. Prostate specific antigen bounce after intensity-modulated radiation therapy in an Asian population. Asian Journal of Urology, 2016, 3(2): 59-63.
Caloglu M, Ciezki J. Prostate-specific antigen bounce after prostate brachytherapy:review of a confusing phenomenon. Urology 2009;74:1183-90.
[2]
Crook J, Gillian C, Yeung I, Austen L, McLean M, Lockwood G. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007;69:426-33.
[3]
Rosser CJ, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee AK. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 2002;168:2001-5.
[4]
Horwitz EM, Levy LB, Kuban DA. The biochemical and clinical significance of the post-treatment PSA bounce for prostate cancer treated with external beam radiation therapy alone:a multi-institutional pooled analysis. Int J Radiat Oncol Biol Phys 2004;60:S235.
[5]
Wallner K, Blasko J, Dattoli MJ. Evaluating cancer status. In:Wallner K, Blasko J, Dattoli MJ, editors. Prostate brachytherapy made complicated, vol. 14. Seattle:SmartMedicine Publishing; 1997. p. 11-5.
[6]
Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000;163:1085-9.
[7]
Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer:descriptions and implications. Int J Radiat Oncol Biol Phys 2003;56:448-53.
[8]
Abel L, Zeroski D, Brammer S, Butler W, Wallner KE, Merrick GS. PSA spike after brachytherapy for localized prostate cancer. Urol Nurs 2007;27:507-10.
[9]
Cavanagh W, Blasko JC, Grimm PD, Sylvester JE. Transient elevation of serum prostate-specific antigen following (125) I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol 2000;18:160-5.
[10]
Ciezki JP, Reddy CA, Garcia J, Angermeier K, Ulchaker J, Mahadevan A, et al. PSA kinetics after prostate brachytherapy:PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 2006;64:512-7.
[11]
Mitchell DM, Swindell R, Elliott T, Wylie JP, Taylor CM, Logue JP. Analysis of prostatespecific antigen bounce after I(125) permanent seed implant for localised prostate cancer. Radiother Oncol 2008;88:102-7.
[12]
Critz FA, Williams WH, Levinson AK, Benton JB, Schnell FJ, Holladay CT, et al. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer:the relationship to patient age. J Urol 2003;170:1864-7.
[13]
Satoh T, Ishiyama H, Matsumoto K, Tsumura H, Kitano M, Hayakawa K, et al. Prostate-specific antigen ‘bounce’ after permanent I-implant brachytherapy in Japanese men:a multiinstitutional pooled analysis. BJU Int 2008;103:1064-8.
[14]
Merrick GS, Butler WM,Wallner KE, Galbreath RW, Anderson RL. Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54:450-6.
[15]
Toledano A, Chauveinc L, Flam T, Thiounn N, Solignac S, Timbert M, et al. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure:a study of 295 patients with a minimum 3-year follow up. Brachytherapy 2006;5:122-6.
[16]
Pickles T. Prostate-specific antigen (PSA) bounce and other fluctuations:which biochemical relapse definition is least prone to PSA false calls? an analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2006;64:1355-9.
[17]
Patel C, Elshaikh MA, Angermeier K, Ulchaker J, Klein EA, Chehade N, et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology 2004;63:110-3.
[18]
Zietmann AL, Christodouleas JP, Shipley WU. PSA bounces after neoadjuvant androgen deprivation and external beam radiation:impact on definitions of failure. Int J Radiat Oncol Biol Phys 2005;62:714-8.
[19]
Waters A, Delouya G, Donath D, Lambert C, Larrivée S, Zorn KC, et al. Risk factors following radiotherapy:outcomes from a multi-modal therapy analysis. Can J Urol 2014;21:7548-53.
[20]
Chira C, Taussky D, Gruszczynski N, Meissner A, Larrivée S, Carrier JF, et al. Unusually high prostate-specific antigen bounce after prostate brachytherapy:searching for etiologic factors. Brachytherapy 2013;6:603-7.
[21]
Pinkawa M, Piroth MD, Holy R, Fischedick K, Schaar S, Borchers H, et al. Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer. Radiother Oncol 2010;96:25-9.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
